Single administration of cerivastatin, an HMG-CoA reductase inhibitor, improves the coronary flow velocity reserve: a transthoracic Doppler echocardiography study

By Takagi Atsushi   Tsurumi Yukio   Ishizuka Naoko   Omori Hisako   Arai Kotaro   Hagiwara Nobuhisa   Kasanuki Hiroshi  

Heart and Vessels, Vol. 21, Iss. 5, 2006-09 ,pp. : 298-301

Springer Publishing Company

Access to resources Recommend Favorite

Direct Vascular Effects of HMG-CoA Reductase Inhibitors

By Laufs U.   Liao J.K.  

Trends in Cardiovascular Medicine, Vol. 10, Iss. 4, 2000-05 ,pp. : 143-148

Elsevier

Access to resources Recommend Favorite

HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis

By Yilmaz A.   Reiss C.   Tantawi O.   Weng A.   Stumpf C.   Raaz D.   Ludwig J.   Berger T.   Steinkasserer A.   Daniel W.G.   Garlichs C.D.  

Atherosclerosis, Vol. 172, Iss. 1, 2004-01 ,pp. : 85-93

Elsevier

Access to resources Recommend Favorite

The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation

By Calkin A.   Giunti S.   Sheehy K.   Chew C.   Boolell V.   Rajaram Y.   Cooper M.   Jandeleit-Dahm K.  

Diabetologia, Vol. 51, Iss. 9, 2008-09 ,pp. : 1731-1740

Springer Publishing Company

Access to resources Recommend Favorite

HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells

By Kunieda Y.   Nakagawa K.   Nishimura H.   Kato H.   Ukimura N.   Yano S.   Kawano H.   Kimura S.   Nakagawa M.   Tsuji H.  

Thrombosis Research, Vol. 110, Iss. 4, 2003-06 ,pp. : 227-234

Elsevier

Access to resources Recommend Favorite